{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:21:51Z","timestamp":1793726511757,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009797","name":"Barrow Neurological Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017770","name":"The Kemper &amp; Ethel Marley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PD190057"],"award-info":[{"award-number":["PD190057"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["MJFF-023919"],"award-info":[{"award-number":["MJFF-023919"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.parkreldis.2025.107294","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T22:44:26Z","timestamp":1737067466000},"page":"107294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Exploring the neuroprotective potential of immunosuppressants in Parkinson's disease"],"prefix":"10.1016","volume":"132","author":[{"given":"Huiam M.","family":"Mubarak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-8235","authenticated-orcid":false,"given":"Brad A.","family":"Racette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3155-1107","authenticated-orcid":false,"given":"Jordan A.","family":"Killion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-1772","authenticated-orcid":false,"given":"Osvaldo J.","family":"Laurido-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Anmisha","family":"Doddamreddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-4736","authenticated-orcid":false,"given":"Susan","family":"Searles Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107294_bib1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/bcp.12804","article-title":"Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders","volume":"82","author":"Maiese","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib2","doi-asserted-by":"crossref","first-page":"e2155","DOI":"10.1212\/WNL.0000000000005678","article-title":"Use of medical care biases associations between Parkinson disease and other medical conditions","volume":"90","author":"Gross","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib3","article-title":"Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries","volume":"18","author":"Song","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2025.107294_bib4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/CLEP.S381289","article-title":"Identification of drugs associated with lower risk of Parkinson's disease using a systematic screening approach in a nationwide nested case-control study","volume":"14","author":"Koponen","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib5","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000207899","article-title":"Association between use of any of the drugs prescribed in Norway and the subsequent risk of Parkinson disease: a drug-wide association study","volume":"101","author":"Romanowska","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","article-title":"The role of glial reaction and inflammation in Parkinson's disease","volume":"991","author":"Hirsch","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.parkreldis.2025.107294_bib7","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","article-title":"Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies","volume":"285","author":"Lee","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2025.107294_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson's disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/acn3.580","article-title":"Immunosuppressants and risk of Parkinson disease","volume":"5","author":"Racette","year":"2018","journal-title":"Annals of clinical and translational neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib10","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1212\/WNL.0000000000013303","article-title":"Disease-modifying antirheumatic drugs and risk of Parkinson disease: nested case-control study of people with rheumatoid arthritis","volume":"98","author":"Paakinaho","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib11","article-title":"Risk of Parkinson disease in Sjogren syndrome administered ineffective immunosuppressant therapies: a nationwide population-based study","volume":"98","author":"Ju","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.parkreldis.2025.107294_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.parkreldis.2018.02.008","article-title":"Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries","volume":"50","author":"Camacho-Soto","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107294_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1212\/WNL.0000000000004536","article-title":"A predictive model to identify Parkinson disease from administrative claims data","volume":"89","author":"Searles Nielsen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000365590","article-title":"A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends","volume":"43","author":"Butt","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.annepidem.2023.04.019","article-title":"A predictive algorithm to identify ever smoking in medical claims-based epidemiologic studies","volume":"85","author":"Faust","year":"2023","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.parkreldis.2025.107294_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib18","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.parkreldis.2025.107294_bib19","first-page":"159","article-title":"Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus","volume":"13","author":"Giordano","year":"2010","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.parkreldis.2025.107294_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","article-title":"Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment","volume":"60","author":"Ravina","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease","volume":"68","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.107294_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3233\/JPD-230313","article-title":"Reduced prevalence of Parkinson's disease in patients prescribed calcineurin inhibitors","volume":"14","author":"Silva","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2025.107294_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.npep.2011.04.002","article-title":"Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application","volume":"45","author":"Osman","year":"2011","journal-title":"Neuropeptides"},{"key":"10.1016\/j.parkreldis.2025.107294_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1582-4934.2004.tb00259.x","article-title":"Molecular mechanisms of neuroprotective action of immunosuppressants--facts and hypotheses","volume":"8","author":"Kaminska","year":"2004","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.parkreldis.2025.107294_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0074-7742(07)79024-4","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"79","author":"Ziemssen","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2025.107294_bib27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","article-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease","volume":"30","author":"Malagelada","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.107294_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.parkreldis.2025.107294_bib29","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1523\/JNEUROSCI.3928-08.2008","article-title":"RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation\/activation","volume":"28","author":"Malagelada","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.107294_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/gtc.13185","article-title":"Rapamycin abrogates aggregation of human alpha-synuclein expressed in fission yeast via an autophagy-independent mechanism","volume":"30","author":"Sugimoto","year":"2025","journal-title":"Gene Cell."},{"key":"10.1016\/j.parkreldis.2025.107294_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/oxfordjournals.aje.a115630","article-title":"The effects of sensitivity and specificity of case selection on validity, sample size, precision, and power in hospital-based case-control studies","volume":"132","author":"Brenner","year":"1990","journal-title":"Am. J. Epidemiol."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:39:53Z","timestamp":1778600393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"alternative-id":["S1353802025000355"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107294","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the neuroprotective potential of immunosuppressants in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107294"}}